India's Gleevec Lu Yong purchases the new version of Gleevec sales network 13621079375

Lu Yong, a patient with chronic myelogenous leukemia at the consultation hotline, discovered that India’s imitation of the Swiss Gleevec anti-cancer drug not only saved domestic patients with chronic myelogenous leukemia more than 10,000 yuan per month in drug expenses, but also meant that their hope of survival greatly increased, so he helped thousands of them. Patients buy this medicine. However, this kind of generic drug has not been approved by the domestic drug regulatory authorities and is considered a fake drug. Recently, Lu Yong was prosecuted on suspicion of selling counterfeit drugs. ("Beijing Times" on March 1)
Life or death, this is not just a Hamlet-like dilemma, but a real dilemma that patients who have had their life-saving drugs turned out to be counterfeit have to face. For patients who cannot afford to take multiple genuine medicines every month, they thought that cheap generic medicines were a life-saving straw. However, in order to survive spontaneously, they fell into the quagmire of fake medicines. Patients who bought medicines for their fellow patients became salesmen. Suspect of counterfeit drugs. To abide by the law is to wait for death, but to live in violation of the law. What is more disturbing and helpless than the disease is probably the mutual exclusion and deadlock between life and the law.
It is undeniable that since drugs are related to health and life, the review and identification of drugs are certainly not optional. Even in accordance with international practice, the United States and the European Food and Drug Administration all adopt strict supervision of drugs to encourage the development of new drugs and ensure drug safety. In this sense, whether it is a domestically produced drug or an imported drug, if it wants to be sold in the Chinese market, it must be registered with the Food and Drug Administration. This requirement is not excessive to say that without registration or registration Even if they are treated as counterfeit drugs, it is nothing more than strict enforcement of the drug review system. Therefore, although it is regarded as a life-saving straw by patients, the cheap generic drugs from India are considered to be fake drugs, and they are not completely innocent.
In fact, the reason why generic drugs from India are/or even lower than genuine drugs is not due to the monopoly benefit bonus under the drug approval power as some netizens believe, but because Indian generic drugs have higher prices for expensive drugs. The avoidance of drug patents has been questioned internationally. Not only that, the online purchasing of overseas drugs is indeed a mixed bag due to the lack of necessary supervision. Especially driven by profit, it is an indisputable fact that genuine and fake drugs appear in this channel. It can be seen that it is indeed not objective and fair to question the legitimacy of the current drug approval system just because generic drugs from India are cheap and good. However, patients who cannot afford genuine drugs, out of survival demands, buy low-priced drugs. For counterfeit drugs, after testing the drug on one's own to verify its efficacy, he shared the hope of life with other patients, and was charged with selling counterfeit drugs. When life-saving medicine turns out to be fake, the instinct to survive actually violates the law and obviously goes against common sense. In any case, life should enjoy the highest right, and protecting people's right to life should be the original intention of any law and system. The drug approval system and drug patent rights are of course no exception.
For example, the compulsory licensing system for pharmaceutical patents is for public health purposes. For drugs that have obtained patent rights, other companies can be granted or licensed to use them without the consent of the patentee. As for India's generic drug industry, although it has patent flaws, the United Nations has promoted the importance of generic drugs at considerable length in its annual report, believing that the development of the generic drug industry is an important step in improving the health level of third world countries. , an important guarantee to improve people's health status, and praise and affirm India's efforts to strengthen the production of low-cost generic drugs.
In this case, under the background that medical insurance cannot provide effective drug supply and life protection for some special patients, generic drugs as the last salvation can obviously not be simply regarded as fake drugs. Patients should work together to help each other, and should cooperate with the sellers of fake drugs. Medicines are differentiated. No matter what, whether to break the law and survive, or obey the law and wait to die, this should not be the patient’s Hamlet question